UBS Group
BBOT

UBS Group’s BridgeBio Oncology BBOT Stock Holding History

UBS Group’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$874K Buy
114,655
+64,205
+127% +$536K ﹤0.01% 5838
2026
Q1 		$452K Sell
50,450
-42,919
-46% -$461K ﹤0.01% 6153
2025
Q4 		$1.17M Buy
93,369
+41,143
+79% +$499K ﹤0.01% 5439
2025
Q3 		$605K Sell
52,226
-16,308
-24% -$170K ﹤0.01% 5946
2025
Q2 		$728K Sell
68,534
-24,126
-26% -$261K ﹤0.01% 5703
2025
Q1 		$1.05M Buy
92,660
+57,712
+165% +$620K ﹤0.01% 5257
2024
Q4 		$367K Buy
34,948
+34,927
+166,319% +$368K ﹤0.01% 6057
2024
Q3 		$219 Buy
+21
New +$217 ﹤0.01% 9055

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

UBS Group's BBOT Position: Q2 2026 in Review

UBS Group increased its BridgeBio Oncology (BBOT) stake by 127% in Q2 2026, buying an estimated $536K and bringing the position to 114,655 shares worth $874K. The position accounts for ﹤0.01% of the portfolio, ranked #5838.

UBS Group first reported a position in BBOT in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.17M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • UBS Group held 114,655 shares of BridgeBio Oncology worth $874K as of Q2 2026.
  • UBS Group bought 64,205 BridgeBio Oncology shares in Q2 2026, an estimated $536K.
  • BridgeBio Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5838 holding.
  • UBS Group first reported a position in BridgeBio Oncology in Q3 2024 and has held it in 8 quarters since.
  • UBS Group's BridgeBio Oncology position peaked at $1.17M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.